Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth

Anti-Cancer Drugs

Volumn 20, Issue 7, 2009, Pages 527-533

  Carrillo, Jaime ^a   Agra, Noelia ^a   Fernández, Noemí ^a   Pestaña, Ángel ^a   Alonso, Javier ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Cholecystokinin; Devazepide; Ewing's tumors

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; DEVAZEPIDE; BENZODIAZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; HORMONE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; EWING SARCOMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; NUDE MOUSE; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZODIAZEPINONES; CELL LINE, TUMOR; DEVAZEPIDE; FEMALE; FLOW CYTOMETRY; HORMONE ANTAGONISTS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHENYLUREA COMPOUNDS; RECEPTORS, CHOLECYSTOKININ; SARCOMA, EWING'S; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70149099106     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832c3a4f     Document Type: Article

References (18)

1. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 2003; 40:276-287.
2. Kovar H. Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. Curr Opin Oncol 1998; 10:334-342.
3. Kovar H. Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 2005; 15:189-196.
4. Janknecht R. EWS-ETS oncoproteins: The linchpins of Ewing tumors. Gene 2005; 363:1-14.
5. Carrillo J, Garcia-Aragoncillo E, Azorin D, Agra N, Sastre A, Gonzalez-Mediero I, et al. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 2007; 13:2429-2440.
6. Rehfeld JF. The endoproteolytic maturation of progastrin and procholecystokinin. J Mol Med 2006; 84:544-550.
7. Beinfeld MC. Biosynthesis and processing of pro CCK: recent progress and future challenges. Life Sci 2003; 72:747-757.
8. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269:G628-G646.
9. Rozengurt E, Walsh JH. Gastrin, CCK, signaling, and cancer. Annu Rev Physiol 2001; 63:49-76.
10. Ferrand A, Wang TC. Gastrin and cancer: a review. Cancer Lett 2005; 238:15-29.
11. Williams JA, Sans MD, Tashiro M, Schafer C, Bragado MJ, Dabrowski A. Cholecystokinin activates a variety of intracellular signal transduction mechanisms in rodent pancreatic acinar cells. Pharmacol Toxicol 2002; 91:297-303.
12. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 1984; 68:167-175.
13. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65:3868-3876.
14. Benini S, Manara MC, Baldini N, Cerisano V, Massimo S, Mercuri M, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001; 7:1790-1797.
15. Smith JP, Kramer S, Bagheri S. Effects of a high-fat diet and L364 718 on growth of human pancreas cancer. Dig Dis Sci 1990; 35:726-732.
16. Lotti VJ, Pendleton RG, Gould RJ, Hanson HM, Chang RS, Clineschmidt BV. In vivo pharmacology of L-364 718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 1987; 241:103-109.
17. Abbruzzese JL, Gholson CF, Daugherty K, Larson E, DuBrow R, Berlin R, et al. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 1992; 7:165-171.
18. Cantor P, Olsen O, Gertz BJ, Gjorup I, Worning H. Inhibition of cholecystokinin-stimulated pancreaticobiliary output in man by the cholecystokinin receptor antagonist MK-329. Scand J Gastroenterol 1991; 26:627-637.